140 related articles for article (PubMed ID: 11844606)
1. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy.
Kawai H; Kiura K; Tabata M; Yoshino T; Takata I; Hiraki A; Chikamori K; Ueoka H; Tanimoto M; Harada M
Lung Cancer; 2002 Mar; 35(3):305-14. PubMed ID: 11844606
[TBL] [Abstract][Full Text] [Related]
2. Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Flens MJ; Scheper RJ; Braakhuis BJ
Br J Cancer; 1998 Feb; 77(4):556-61. PubMed ID: 9484811
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
4. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of a cisplatin-resistant human neuroblastoma cell line.
Yasuno T; Matsumura T; Shikata T; Inazawa J; Sakabe T; Tsuchida S; Takahata T; Miyairi S; Naganuma A; Sawada T
Anticancer Res; 1999; 19(5B):4049-57. PubMed ID: 10628353
[TBL] [Abstract][Full Text] [Related]
7. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
8. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
9. Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines.
Hour TC; Chen J; Huang CY; Guan JY; Lu SH; Hsieh CY; Pu YS
Anticancer Res; 2000; 20(5A):3221-5. PubMed ID: 11062746
[TBL] [Abstract][Full Text] [Related]
10. Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells.
Doherty B; Lawlor D; Gillet JP; Gottesman M; O'Leary JJ; Stordal B
Anticancer Res; 2014 Jan; 34(1):503-7. PubMed ID: 24403508
[TBL] [Abstract][Full Text] [Related]
11. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.
Giaccone G; van Ark-Otte J; Rubio GJ; Gazdar AF; Broxterman HJ; Dingemans AM; Flens MJ; Scheper RJ; Pinedo HM
Int J Cancer; 1996 Jun; 66(6):760-7. PubMed ID: 8647646
[TBL] [Abstract][Full Text] [Related]
12. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
[TBL] [Abstract][Full Text] [Related]
13. Effects of vinorelbine on cisplatin resistance reversal in human lung cancer A549/DDP cells.
Zhou YT; Li K; Tian H
Asian Pac J Cancer Prev; 2013; 14(8):4635-9. PubMed ID: 24083716
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
15. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of renal cell carcinoma cell lines with multidrug resistance.
Yu DS; Ma CP; Chang SY
Urol Res; 2000 Apr; 28(2):86-92. PubMed ID: 10850629
[TBL] [Abstract][Full Text] [Related]
17. Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line.
Gonzalez Manzano R; Versanvoort C; Wright K; Twentyman PR
Eur J Cancer; 1996 Nov; 32A(12):2136-41. PubMed ID: 9014757
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
Cheng G; Li Y; Tian F
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
[TBL] [Abstract][Full Text] [Related]
19. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype.
Kotoh S; Naito S; Yokomizo A; Kohno K; Kuwano M; Kumazawa J
J Urol; 1997 Mar; 157(3):1054-8. PubMed ID: 9072542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
